• DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Viewpoints

EU-African Union summit – Why we need to invest in clinical research infrastructure in Africa

Home > Viewpoints

EU-African Union summit – Why we need to invest in clinical research infrastructure in Africa

Healthcare worker in lab setting
17 Feb 2022
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

This is a slightly modified and edited version of an opinion piece published by the EU Observer on 16 February 2022.

As European and African heads of state gather in Brussels to discuss deepening ties – including the burning issues of equitable access to COVID-19 vaccines and treatments and the need for drug manufacturing in Africa – we, as African and European scientists, believe another issue should feature high on the agenda: the development of robust clinical research infrastructure across the continent.

This is critical, not only to be prepared for future disease outbreaks, but also to support the Summit’s objectives of building lasting prosperity across Africa. Outdated, ‘trickle-down’ approaches to scientific cooperation, inherited from colonial times, will not work. And the EU-AU summit presents a historic opportunity to do things differently by discussing investment in science infrastructure in Africa.

We speak with the confidence of researchers who have witnessed the outstanding achievements of African scientists who, with adequately resourced research infrastructure, have more than proved their capabilities. But throughout the COVID-19 pandemic, we have also observed with dismay the lack of proper global investment and coordination in key areas to address the health needs of African communities. Fewer than 6% of clinical trials for COVID-19 worldwide have been carried out in Africa.

This story is not new. The African continent is home to around 15% of the world’s population and 25% of the global disease burden. Yet only 1.1% of global investment in health research and development (R&D) is spent in Africa.

This imbalance increases the risk of a ‘brain drain’ of Africa’s talented scientists, who may have no choice but to exercise their skills outside the continent in research environments with better funding and more modern equipment.

It’s time to turn the tide.

COVID-19 has highlighted the importance of building African clinical research infrastructure to support pandemic response and preparedness. The African Centers for Disease Control (CDC), based in Ethiopia, has played a major role in coordinating pandemic control efforts. We have seen how those African countries with strong medical research capacity were better able to respond to COVID-19. For example, Botswana was the first country able to detect the emergence of the Omicron variant, thanks to its sequencing capacities.

The European & Developing Countries Clinical Trials Partnership (EDCTP) funded the setup of the African coaLition for Epidemic Research, Response and Training (ALERRT) and the Pan-African Network For Rapid Research, Response, Relief and Preparedness for Infectious Disease Epidemics (PANDORA-ID-NET) after the Ebola crisis. These networks dedicated to research in epidemics have proven useful in marshalling forces to conduct important research in Africa and support the COVID response.

That is why investing now to strengthen African-based, African-led collaborative research platforms is a smart move. True global pandemic preparedness requires robust infectious disease surveillance and control networks everywhere on the globe, including in low- and middle-income countries. Bolstering African research infrastructure will allow the continent – and the world – to respond more effectively when faced with the next infectious threat.

The good news is that African medical research expertise and experience is plentiful; too often missing, however, are the resources and platforms needed to bring that talent together.

For those diseases for which such platforms do exist, there has been an impressive track record of success. An outstanding example is the response to the 2014-2016 Ebola crisis in West Africa, which saw African and global networks mobilizing quickly to conduct robust vaccine research in one of the most difficult social and medical environments ever faced by researchers. Vaccine trials in Guinea, Liberia and Sierra Leone, for example, were conducted in the most trying circumstances but deployed pioneering research, paving the way for safe, effective and widely accessible Ebola vaccines in the future.

Or take the Democratic Republic of Congo (DRC), where scientists have carried out clinical trials to the highest international standards in extremely remote areas and under challenging conditions. The game-changing drugs they developed for a neglected disease called ‘sleeping sickness’ have helped the DRC to envision the elimination of a disease that killed hundreds of thousands in the past century.

The ANTICOV consortium is another collaborative medical research initiative in Africa, now testing treatments for patients with mild-to-moderate COVID-19 across 13 African countries with researchers from leading African institutions in the driver’s seat.

ANTICOV could be seen as an example of the wider research platforms that we are calling for to connect science and public health institutions, ensure research is relevant to the needs of different countries, support faster development of treatments and testing tools, and later provide rapid response to future disease outbreaks.

From past successes, we believe that building such a clinical network is within our reach. However, to be sure of achieving this, we need to see sustained investment in the human and technical resources needed to ensure platforms can be flexible, autonomous, able to respond promptly and effectively to emerging outbreaks, and capable of supporting efforts to tackle ongoing health priorities across the continent.

We see enormous competence and commitment among African scientists, but also the frustration and anxiety that comes with not having all the tools needed to respond to future health crises. With dedicated resources and political will, we believe the future of medical research on the continent can be bright.

We need European and African decision makers gathering this week in Brussels to see and harness this potential, to promote scientific excellence, and contribute to a shared healthy future for us all.


By Samba Sow (Director of the Center for Vaccine Development in Bamako, Mali), Marie-Paule Kieny (Director of Research at INSERM in Paris, France), John Amuasi (Group Leader of the Global Health and Infectious Diseases Research Group, Kumasi Center for Collaborative Research in Tropical Medicine, Ghana), Serge Eholie (Head of Infectious Diseases at Treichville University Teaching Hospital in Abidjan, Côte d’Ivoire), Francine Ntoumi (Founding Director of the Congolese Foundation for Medical Research in Brazzaville, Republic of Congo), Jürgen May (Chairman of Bernhard Nocht Institute for Tropical Medicine in Hamburg, Germany), Dieudonné Mumba (Head of Parasitology at the National Institute of Biomedical Research in Kinshasa, RD Congo), Bernhards Ogutu (Chief Research Officer at the Kenya Medical Research Institute in Nairobi, Kenya), Nathalie Strub-Wourgaft (Director at the Drugs for Neglected Diseases initiative in Geneva, Switzerland), Marc-Alain Widdowson (Director of the Institute of Tropical Medicine in Antwerp, Belgium) and Yazdan Yazdanpanah (Director of ANRS Emerging Infectious Disease Funding Agency in Paris, France)

Photo credit: Kenny Mbala-DNDi

Funding Strengthening Capacities Africa

Read, watch, share

Loading...
Woman standing in front of a house
Press releases
2 Feb 2023

Dutch government renews support to DNDi projects on poverty-related diseases that disproportionately impact women

Statements
1 Feb 2023

DNDi interventions at the 152nd session of the WHO Executive Board

Young man sitting in hospital setting
News
25 Jan 2023

It’s time medical innovation reached the 1.7 billion people affected by neglected tropical diseases: World NTD Day 2023

Film Poster Voices of Leishmaniasis: Shushi from India
Videos
25 Jan 2023

Voices of leishmaniasis: Shishu from India

Child receiving treatment
News
20 Jan 2023

DNDi’s 20th year of bringing the best science for the most neglected

Child affected by dengue and her mother at their home in Bangkok, Thailand.
Stories
16 Dec 2022

2022: Six advances in neglected disease research to remember

Statements
2 Dec 2022

DNDi‘s comments on the conceptual zero draft for the consideration of the Intergovernmental Negotiating Body at INB3

Healthcare workers discussing in hospital setting
Press releases
1 Dec 2022

DNDi partners in a new NIHR-funded Global Health Research Group on HIV-associated Fungal Infections (IMPRINT)

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo